HOTH THERAPEUTICS INC (HOTH) Stock News

USA - Nasdaq - NASDAQ:HOTH - US44148G2049 - Common Stock

1.1833 USD

-0.02 (-1.39%)

Last: 12/8/2025, 11:17:53 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

HOTH Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

7 days ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

18 days ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

2 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

2 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

2 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

3 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

3 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

3 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

3 months ago - By: Benzinga - Mentions: BRKR SLRX PPCB LUNG ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

3 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

3 months ago - By: Benzinga - Mentions: SILO

EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers

4 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

5 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

6 months ago - By: Silo Pharma, Inc. - Mentions: SILO

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

6 months ago - By: Hoth Therapeutics, Inc. - Mentions: SILO

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty

6 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

6 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

6 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

6 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

6 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics to Attend 2025 BIO International Convention

6 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

6 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

6 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

7 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

8 months ago - By: Hoth Therapeutics, Inc.

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform